METHODOLOGY

Alternative ultraviolet A lamp for corneal collagen crosslinking

Manuel Diaz-Llopis David Salom Salvador Garcia-Delpech Patricia Udaondo Maria Garcia-Pous

Department of Ophthalmology, La Fe University Hospital of Valencia, Valencia, Spain

Correspondence: David Salom La Fe University Hospital, Bulevar del Sur, 46026 Valencia, Spain Tel +34 961 24 40 00 Email david.salom@yahoo.com **Abstract:** In this paper, we describe an original, affordable, and available device for performing collagen crosslinking. This is carried out in a safe and reproducible way by means of a simple modification to an affordable ultraviolet A lamp and by preparing riboflavin 0.1% solution inhouse.

Keywords: corneal collagen crosslinking, keratoconus treatment, ultraviolet A lamp

Introduction

In recent years, corneal specialists have shown a fast growing interest in collagen crosslinking using the photosensitizer riboflavin and ultraviolet A light as a new therapeutic alternative for the treatment of progressive keratoconus. The aim of this treatment is to modify the biomechanical properties of the cornea, thus increasing its rigidity and preventing the progression of keratoconus.¹ Promising results have been published recently, and data from the Dresden clinical study have shown stabilization of the disease, even after 5 years.^{2,3}

It is necessary to follow strict treatment settings and patient eligibility criteria to avoid serious ocular side effects. The patient's cornea must be irradiated with a small peak-like sector of the ultraviolet A spectrum (370 nm) with 3 mW/cm² irradiance for 30 minutes, which corresponds to a dose of 5.4 J/cm².³ The ultraviolet A irradiance must be checked before each treatment using an ultraviolet A meter to ensure that the optimal irradiance dose is delivered. The photosensitizing riboflavin 0.1% solution must be applied 5 minutes before irradiation and every 5 minutes during irradiation. It is also essential to perform preoperative pachymetry on each patient to exclude those with extended areas of less than 400 µm of stromal thickness.

We describe how to perform collagen crosslinking in the protocol setting using a slightly modified ultraviolet A dermatological lamp and preparing the riboflavin 0.1% solution inhouse. The cost of the treatment is lower, while maintaining its safety and efficacy.

Materials and methods

We used a slightly modified 370 nm ultraviolet A lamp (UV 109A, Waldmann, Villingen-Schwenningen, Germany) designed for dermatological treatment (Figure 1A), covered with a black plastic adhesive tape leaving a small window through which ultraviolet light can reach the cornea (Figure 1B). The desired irradiance of 3 mW/cm^2 is tested with a ultraviolet A meter (Waldmann) before each treatment,

submit your manuscript | www.dovepress.com Dovepress http://dx.doi.org/10.2147/OPTH.S33866 Clinical Ophthalmology 2013:7 557-559

© 2013 Diaz-Llopis et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.



Figure I Alternative device for collagen crosslinking. (A) A 370 nm ultraviolet A lamp designed for dermatological treatment. (B) The ultraviolet A lamp is covered with a black plastic adhesive tape that leaves a small window through which ultraviolet light can reach the cornea.

thus establishing the optimal distance from the ultraviolet A lamp to the cornea. This distance was 3.5 cm with the ultraviolet A lamp we used. The lamp was held by a clamp mounted on an intravenous pole (Figure 2). Patients' corneas were irradiated with 3 mW/cm² of ultraviolet A (370 nm) for 30 minutes.

The riboflavin 0.1% solution was prepared just before treatment by mixing 10 mg of riboflavin-5-phosphate (Guinama, Valencia, Spain) with 10 mL of dextran 20% solution. The solution was introduced into an empty 15 mL balanced salt solution bottle (Alcon Laboratories, Fort Worth, TX, USA) wrapped in aluminum foil to avoid exposure of the riboflavin to ambient light (Figure 3) through a 0.22 μ m sterilization filter (Millipore Corporation, Bedford, MA, USA). The entire process was performed under sterile conditions. The riboflavin 0.1% solution was applied 5 minutes before irradiation and every 5 minutes during irradiation.

Results

Thus far, we have successfully treated 12 patients with progressive keratoconus using this ultraviolet A lamp and riboflavin 0.1% solution (Figure 4) prepared inhouse. Visual acuity remained stable in all cases after 6 months. Stabilization of corneal topography was observed in all



Figure 2 Ultraviolet A lamp held by a clamp mounted on an intravenous pole.



Figure 3 Riboflavin 0.1% solution in a 15 mL balanced salt solution bottle wrapped in aluminum foil to avoid exposure to ambient light.

patients after 6 months. No side effects were detected in the early postoperative period or after 6 months.

Discussion

We have developed an alternative possibility for collagen crosslinking. The modifications needed to the ultraviolet A lamp were simple and easy to perform. The riboflavin solution was also easily prepared in the clinical pharmacy of the hospital by trained personnel. One important issue to be mentioned is the fact that the limbus should be protected against irradiation, and a round 8 mm hole in the tape that covers the lamp could be made for this purpose.

The price of a commercially available ultraviolet A lamp designed for collagen crosslinking is approximately \notin 15,000, and the riboflavin solution prepared inhouse costs approximately \notin 60 per patient. The price of the slightly modified ultraviolet A dermatological lamp we used is approximately



Figure 4 Performing collagen crosslinking in a progressive keratoconus patient with the modified ultraviolet A lamp and the self-made riboflavin 0.1% solution at 3.5 cm from the cornea.

\$400, the riboflavin 0.1% solution we prepared inhouse costs \$2.20 per patient, and the ultraviolet light meter price costs around \$200. This provides ophthalmologists worldwide with an affordable alternative device for collagen crosslinking, especially for those in developing countries or places where resources are limited.

Disclosure

The authors report no conflicts of interest in this work.

References

- 1. Wollensak G. Crosslinking treatment of progressive keratoconus: new hope. *Curr Opin Ophthalmol*. 2006;17(4):356–360.
- Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006;32(5):837–845.
- Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet A-induced collagen crosslinking for the treatment of keratoconus. *Am J Ophthalmol.* 2003;135(5):620–627.

Clinical Ophthalmology

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on

Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal

PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Dovepress